Stereotaxis Q2 Revenue Nearly Doubles Post-APT Acquisition; Margins Compressed, Cash Falls

Stereotaxis, Inc. (NASDAQ: STXS) - Quick take

All dollar amounts below are reported in thousands except share counts and per-share figures (company 10‑Q for period ended June 30, 2025).

Snapshot - what's happening inside
* Company is scaling revenue after the July 2024 APT acquisition and new product clearances (GenesisX CE mark, MAGiC CE; MAGiC Sweep™ received FDA 510(k) in July 2025).
* Integration of Access Point Technologies (APT) is underway - APT contributed $2,562 of revenue post-acquisition in the six months ended June 30, 2025 and the acquisition carries contingent consideration and added inventory/operational complexity.
* Management is managing cash tightly: cash and cash equivalents fell to $6,967 at June 30, 2025 from $12,217 at Dec 31, 2024, and working capital was reported as $1,200 (six‑month commentary). To bolster liquidity the company completed a registered direct offering in July 2025 (4,250,000 shares at $2.00 = $8.5M initial proceeds; $4.0M additional closing expected Nov 25, 2025; total offering $12.5M).

Key numbers (from the 10‑Q)
* Total revenue - Three months ended June 30, 2025: $8,798 vs. Q2 2024: $4,502 (increase 95%). Six months ended June 30, 2025: $16,270 vs. 2024: $11,382 (increase ~43%).
* Revenue split (Q2 2025) - Systems: $3,038; Disposables, service & accessories: $5,760.
* Cost of revenue (Q2 2025) - Total: $4,219 (Systems: $2,366; Disposables: $1,853).
* Gross margin - Q2 2025: $4,579 (52%) vs Q2 2024: $3,313 (74%). Six months 2025: $8,643 (53%) vs six months 2024: $7,279 (64%).
* Operating loss - Q2 2025: $(3,977) vs Q2 2024: $(6,021) (improved). Six months 2025: $(9,906) vs six months 2024: $(10,767).
* Net loss attributable to common stockholders - Q2 2025: $(4,144); Q2 2024: $(6,158). Six months 2025: $(10,281); six months 2024: $(10,996).
* Net loss per share attributable to common stockholders - Q2 2025: $(0.05) vs Q2 2024: $(0.07). Six months 2025: $(0.12) vs $(0.13).
* Cash & equivalents - $6,967 (June 30, 2025) vs $12,217 (Dec 31, 2024). Total cash, cash equivalents, and restricted cash at period end: $6,967.
* Inventories - $9,608 (June 30, 2025) vs $8,331 (Dec 31, 2024). Reserve for excess & obsolescence: $2,657.
* Deferred revenue (total) - $6,900 (June 30, 2025) vs $8,868 (Dec 31, 2024). Transaction price allocated to remaining performance obligations on system contracts ~ $12,200 as of June 30, 2025.
* Contingent consideration - Current: $5,839; Long-term: $6,384 (total ~$12,223). Company recorded $458 expense for revaluation of contingent consideration in six months ended June 30, 2025.
* Accumulated deficit - $(571,374) as of June 30, 2025. Total stockholders' equity - $1,456 (June 30, 2025). Total assets - $41,173; Total liabilities - $34,421.
* Outstanding common shares - 90,653,769 (as of July 31, 2025 per filing header). No debt reported as of June 30, 2025.

Income statement - positives
* Strong revenue growth: Q2 revenue nearly doubled year-over-year (from $4,502 to $8,798). Six‑month revenue rose ~43% year‑over‑year.
* Systems sales scaled materially (Q2 systems revenue $3,038 vs $240 prior year quarter) - showing capital sale traction after product approvals and commercial activity.
* Operating and net losses improved vs. prior year comparable periods (operating loss Q2 improved from $(6,021) to $(3,977); net loss Q2 improved from $(5,833) to $(3,826)).
* Company has no debt and completed an equity raise in July 2025 to strengthen liquidity (initial $8.5M received).

Income statement - negatives / risks
* Gross margin compressed: overall margin fell from 74% to 52% in Q2 (64% to 53% for six months) - primarily due to product mix shifts and acquisition accounting (inventory stepped up to fair value) that lowered disposables margin.
* Continued losses and cash burn: six-month net loss $(9,649) and operating cash use $(5,512) - cash balances declined materially to $6,967 at June 30, 2025 before the July equity raise.
* Acquisition-related costs: acquisition of APT added contingent consideration (~$12.0M), intangible amortization and integration expenses; fair-value remeasurement added $458 of expense in six months.
* Inventory build and obsolescence reserve ($2,657) - risk if demand shifts or inventory turns slowly.
* Deferred revenue and customer deposits declined (deferred revenue $6,900 from $8,868; customer deposits $1,368 from $2,687) - indicates some slowdown in advance billings or timing differences.
* Exposure to tariffs, supply‑chain disruptions and hospital capital cycles noted - these could pressure gross margins, system placements, and recurring disposable revenue.

Operational takeaways
* Growth story is visible: system installations and disposables revenue are ramping after regulatory wins and the APT deal, but margin pressure from product mix and acquisition accounting is real and measurable.
* Liquidity is manageable short term (no debt, recent $8.5M initial equity proceeds with $4.0M expected later), but cash remains limited relative to recurring operating losses - future fund raises or improved operating cash flow will be needed to sustain product commercialization and R&D.
* Contingent consideration and stock-based compensation (including a material CEO performance award) are non‑cash drivers of expense that will affect reported results and potential dilution over time.

Bottom line
Stereotaxis (NASDAQ: STXS) is showing clear revenue acceleration and commercial momentum after product approvals and the APT acquisition, but profitability remains negative, gross margins compressed, cash balances have drawn down and acquisition-related contingent liabilities and integration risks create uncertainty. The July 2025 equity raise eases near-term liquidity pressure, but the company still needs sustained margin improvement or additional financing to reach cash-flow break-even.